alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Deletion'],"[{'ncitCode': 'C185417', 'drugName': 'AMG 193'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],['39293516'],"[{'link': 'https://www.annalsofoncology.org/article/S0923-7534(24)02190-2/fulltext', 'abstract': 'Sacher et al. Abstract# 604O, ESMO 2024.'}]","AMG 193 is an orally available, small-molecule PRMT5 inhibitor that inhibits PRMT5 methyltransferase activity to increase expression of antiproliferative genes. In the Phase I/II first-in-human (NCT05094336) trial of AMG 193 in 47 patients with advanced MTAP-null solid tumors (n= 10, pancreatic ductal adenocarcinoma [PDAC]; n=6, non-small cell lung cancer [NSCLC]; n=5, cholangiocarcinoma [CCA]; n=3, mesothelioma [MESO]; n=23, other), the objective response rate (ORR) was 21.4% (95% CI= 10.3-36.8), and partial response was achieved in five patients (n=1, PDAC [35+ weeks]; n=1, ovarian Sertoli-Leydig [32+ weeks]; n=1, gallbladder [20 weeks]; n=1, renal cell carcinoma [28+ weeks]; n=1, esophageal [24 weeks]) and stable disease was achieved in 16 patients (n=1, bladder; n=3, NSCLC; n=1, small intestine; n=1, salivary; n=3, PDAC; n=1, MESO; n=1, sarcoma; n=1, neuroendocrine tumor; n=1, pulmonary pleomorphic carcinoma; n=1, gastrointestinal stromal tumor; n=2, CCA) (PMID: 39293516). In the initial dose expansion results of the Phase I (NCT05094336) trial of AMG 193, patients with MTAP-null NSCLC (n=11) demonstrated an ORR of 18.2% (95% CI=2.3-51.8) and disease control rate (DCR) of 45.5% (95% CI=16.7-76.6), patients with MTAP-null PDAC (n=16) demonstrated an ORR of 12.5% (95% CI=1.6-38.3) and a DCR of 43.8% (95% CI=19.8-70.1) and patients with MTAP-null biliary tract cancer (n=11) demonstrated an ORR of 18.2% (95% CI=2.3-51.8) and DCR of 36.4% (95% CI=10.9-69.2) (Abstract: Sacher et al. Abstract# 604O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02190-2/fulltext). Preclinical studies with patient-derived tumor samples demonstrate sensitivity to AMG 193 as measured by the inhibition of the production of the PRMT5/MTAP metabolite SDMA (PMID: 39293516)."
['Deletion'],"[{'ncitCode': 'C187048', 'drugName': 'MRTX1719'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],['37552839'],[],"MRTX1719 is an orally available, small-molecule PRMT5-MTA complex inhibitor that targets the elevated expression of the PRMT5-MTA complex found in MTAP-deleted cells. In the phase I/II study 1719-001 (NCT05245500) trial of MRTX1719 in 18 patients with solid tumors harboring MTAP gene deletions, partial response was achieved in 6 patients (n=2, malignant mesothelioma [24+ weeks]; n=1, non-small cell lung cancer [18+ weeks]; n=1, malignant melanoma [45+ weeks]; n=1, gallbladder adenocarcinoma [39+ weeks]; n=1, malignant peripheral nerve sheath tumor [12+ weeks]) (PMID: 37552839). Preclinical studies in MTAP-deleted cancer cell lines, xenograft models and tumor biopsies demonstrate sensitivity to MRTX1719 as measured by inhibition of the production of PRMT5/MTAP metabolite SDMA, dose-dependent tumor shrinkage and inhibition of cellular proliferation (PMID: 37552839)."
